Compare BoBo Balance vs Creative Therapy
Customers evaluate the quality of BoBo Balance's products using the following success metrics.
BoBo Balance is 7 yrs old and is based in Israel.
BoBo Balance provides a fitness device that connects to users' devices with a mobile application. It offers a balancing device that helps to improve focus, motor skills, strength, performance, and more. It allows users to hop on the motion sensor device and play online games on their mobile devices. Its products include BoBo Wobbly, BoBo Home, and BoBo Pro 2.0. The company was founded in 2017 and is based in Rosh Haayin, Israel.
Creative Therapy is 5 yrs old and is based in Belgium.
Creative Therapy is a company focused on providing therapeutic solutions in the healthcare industry. The company offers products that help improve balance, coordination, reflexes, muscle strength, and mobility, as well as tools for tracking patient progress during therapy. These services are primarily targeted towards the healthcare sector. It was founded in 2019 and is based in Ghent, Belgium.
Google for Startups Growth Academy: AI for Cybersecurity
Information not available because BoBo Balance has not claimed their profile.
Work for BoBo Balance? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for BoBo Balance?
Claim your profile now.
Why Creative Therapy beats BoBo Balance
- Amount of implementation opportunities with patients during therapy.
- Ease of use and speed of use
- Time saved while patients where exercising on Matti
Interactive mat with pressure sensors and LEDs which can connect to an online platform. Matti supports physiotherapists to deliver motivational and personalised therapy exercises to their patients while tracking their progress. Matti is used for patients with Acuired Brain Injuries, Obesity, Muscoletal injuries, Cerebral Palsy, ...
Creative Therapy works with 1 known companies.
Why They Buy
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.